Palisade Bio, Inc. - PALI
About Gravity Analytica
Recent News
- 02.10.2025 - Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
- 01.29.2025 - Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress
- 01.22.2025 - Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
- 01.16.2025 - Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis
- 01.03.2025 - Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- 12.17.2024 - Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board
- 12.13.2024 - Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
- 12.12.2024 - Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules